Over the past few years, cell and gene therapies have gained significant popularity owing to their therapeutic potential.
In fact, more than 20 genetically modified therapies have already been approved, which has resulted in the increase in demand for vectors, which have proven to be highly efficient for the delivery of genetic material to the targeted area. In order to cater to the growing demand, several companies are offering diverse range of services for vector and gene therapy manufacturing.
By 2035, the financial opportunity within the viral vector manufacturing, non-viral vector manufacturing and gene therapy manufacturing market has been analyzed across the following segments:
Scale of Operation
Lab
Clinical
Commercial
Type of Vectors
AAV
Adenoviral
Lentiviral
Retroviral
Plasmid DNA
Other Vectors
Application Area
Gene Therapy
Cell Therapy
Vaccines
Therapeutic Area
Oncological Disorders
Rare Disorders
Neurological Disorders
Sensory Disorders
Metabolic Disorders
Musco-skeletal Disorders
Blood Disorders
Immunological Diseases
Others
Geographical Regions
North America
Europe
Asia Pacific
Latin America
MENA
Rest of the World
The “Viral Vector, Non-Viral Vector and Gene Therapy Manufacturing Market (5th Edition), 2022-2035” report features the following companies, which we identified to be key players in this domain:
Advanced BioScience Laboratories
Aldevron
Audentes Therapeutics
BioNTech Innovative Manufacturing
BioReliance
Biovian
bluebird bio
Cell and Gene Therapy Catapult
Celonic
Centre for Process Innovation
Cobra Biologics
Emergent BioSolutions
FinVector
FUJIFILM Diosynth Biotechnologies
Kaneka Eurogentec
Lonza
MeiraGTx
MolMed
Novasep
Orchard Therapeutics
Oxford BioMedica
Richter-Helm
Sanofi
Spark Therapeutics
Thermo Fisher Scientific
uniQure
Vibalogics
Vigene Biosciences
VIVEbiotech
Wuxi AppTech
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Viral Vector and Gene Therapy Manufacturers (Industry Players): Market Landscape
1. Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Market Landscape
2. Vector And Gene Therapy Manufacturers (Non-Industry Players): Market Landscape
3. Vector And Gene Therapy Manufacturing Technologies: Market Landscape
4. Company Competitiveness Analysis
5. Vector And Gene Therapy Manufacturers in North America
6. Vector And Gene Therapy Manufacturers in Europe
7. Vector And Gene Therapy Manufacturers in Asia-Pacific
8. Other Key Players
9. Recent Partnerships
14. Recent Expansions
15. Strategic Partner Analysis
16. Emerging Vectors
17. Key Insights
18. Cost Price Analysis
19. Capacity Analysis
20. Demand Analysis
21. Market Sizing and Opportunity Analysis
22. Porter’s Five Forces Analysis
23. Key Drivers and Challenges
24. Survey Analysis
25. Concluding Remarks
26. Executive Insights
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/274.html
You may also be interested in the following titles:
Pharmaceutical Polymers / Medical Polymers Market
Gene Switch Market
You may also like to learn what our experts are sharing in Roots educational series:
Rare Kidney Disorders: Future Miracle Drugs
Smart pharmaceutical and healthcare labels: Lets trace medicines from its origin
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com
